- 24 January 2012
ICON Strengthens Global Scientific Council with the Appointments of Professor Brendan Buckley and Dr. Nicholas Alp
ICON’s Scientific Council is a team of ICON experts with broad industry experience and knowledge of the scientific, technical and therapeutic aspects of product development, from concept through to approval.
- 09 January 2012
ICON Selected by Shire plc’s Specialty Pharmaceuticals division as Global Strategic Partner for Clinical Research and Central Laboratory Services
ICON has signed a strategic partnership with Shire plcs's Specialty Pharmaceuticals which will see it serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.
- 27 December 2011
ICON Announces Dr. Anthony Murphy To Retire From Board of Directors
ICON today announced the retirement of Non-Executive Director, Dr. Anthony Murphy to become effective on 31st December 2011.
- 12 December 2011
ICON Acquires BeijingWits Medical Consulting Ltd
ICON today announced that it has agreed, subject to closing conditions, to acquire BeijingWits Medical Consulting Ltd., a leading CRO in China. The transaction is expected to close in the first quarter of 2012.
- 28 November 2011
ICON Development Solutions Appoints Dr. Daniel Tang as General Manager Asia Pacific
ICON today announced that its Development Solutions division has appointed Dr. Daniel Tang as General Manager, Asia Pacific. Dr. Tang will lead the development of ICON’s early phase activities across the region, including bioanalytical laboratory services, and the development of strong links with Key Opinion Leaders for early phase clinical testing.
- 22 November 2011
ICON plc Commencement of Share Repurchase Programme
ICON will now begin to repurchase shares pursuant to the approval by its Board of Directors of a share buyback of up to $50m, as indicated in the Company’s Q3 results issued on 27 October 2011.
- 21 November 2011
Tasly Pharmaceuticals Selects ICON as it Seeks First FDA Approval of a Traditional Chinese Medicine
ICON today announced that it has been selected by Tasly Pharmaceuticals 600535.SH) for the company’s global Phase III T89 trial. T89, also known as Dantonic® pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States.
- 17 November 2011
ICON Medical Imaging Rated as Top Provider in Imaging Industry Survey
ICON today announced that its Medical Imaging division was rated as the top provider of imaging services according to an industry survey conducted by Blue Pyramid Consulting, an affiliate of the Avoca Group.
- 16 November 2011
DOCS Continues Expansion with four new offices in Europe
ICON's resourcing division, DOCS, has opened four new offices in Milan, Italy; Budapest, Hungary; Brussels, Belgium and Berlin, Germany.
- 09 November 2011
ICON PLC and Empire Genomics Partner for the Delivery of Personalised Medicine Services
ICON and Empire Genomics, a leading provider of genomic technologies that enable personalised medicine to be realised, today announced the formation of a strategic alliance.
